Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines
Research output: Contribution to journal › Review › Research › peer-review
Standard
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. / Guo, Yi; Bera, Hriday; Shi, Changzhi; Zhang, Li; Cun, Dongmei; Yang, Mingshi.
In: Acta Pharmaceutica Sinica B, Vol. 11, No. 8, 2021, p. 2565-2584.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines
AU - Guo, Yi
AU - Bera, Hriday
AU - Shi, Changzhi
AU - Zhang, Li
AU - Cun, Dongmei
AU - Yang, Mingshi
N1 - Funding Information: We thankfully acknowledge the Liaoning Pan Deng Xue Zhe scholarship for the financial support (China). Dongmei Cun thanks the financial support from the Guiding Project for Science and Technology of Liaoning Province (No. 2019-ZD-0448 , China), and Minister of Education Chunhui Program (China). Hriday Bera thanks the National Natural Science Foundation of China (Nos. 81850410554 and 82050410448). Publisher Copyright: © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
PY - 2021
Y1 - 2021
N2 - Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.
AB - Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.
KW - Inhaled sustained release formulations
KW - Local lung diseases
KW - Pharmaceutical strategies
KW - Pulmonary clearance pathways
KW - Pulmonary drug delivery
KW - Pulmonary exposure
KW - Pulmonary safety
KW - Systemic diseases
U2 - 10.1016/j.apsb.2021.05.015
DO - 10.1016/j.apsb.2021.05.015
M3 - Review
C2 - 34522598
AN - SCOPUS:85111482770
VL - 11
SP - 2565
EP - 2584
JO - Acta Pharmaceutica Sinica B (Online)
JF - Acta Pharmaceutica Sinica B (Online)
SN - 2211-3843
IS - 8
ER -
ID: 281218855